Table 3.
Survival analysis for different subgroups of patients included into the study: number of patients, median survival with 95% confidence interval (CI), actuarial 3- and 5-year survival and P-value of the log rank test
| Variable | n | Median survival (Months) | 95% CI | 3-y surv (%) | 5-y surv (%) | P |
|---|---|---|---|---|---|---|
| Overall | 62 | 21.9 | 18.2–25.5 | 30 | 15 | – |
| LN | 0.032 | |||||
| N0 | 32 | 41.9 | 13.3–70.4 | 50 | 25 | |
| N+ | 21 | 22.7 | 18.2–27.2 | 0 | 0 | |
| LN harvested | 0.001 | |||||
| 0 LN | 9 | 3 | 1.0–5.9 | 0 | 0 | |
| 1–3 LN | 18 | 18.5 | 12.7–24.2 | 25 | 16 | |
| >3 LN | 35 | 28.8 | 17.0–46.6 | 41 | 16 | |
| Positive LN | 0.721 | |||||
| 1–3 N+ | 14 | 22.7 | 10.1–35.3 | 0 | 0 | |
| >3 N+ | 7 | 25 | – | 0 | 0 | |
| Negative LN | 0.152 | |||||
| 1–3 N0 examined | 14 | 18.5 | 13.1–23.8 | 31 | 20 | |
| >3 N0 examined | 18 | 43.1 | 25.6–60.5 | 68 | 27 | |
| LNR | 0.031 | |||||
| ≤0.25 | 42 | 26 | 16.2–35.8 | 44 | 22.5 | |
| >0.25 | 9 | 22.7 | 1.0–45.0 | 0 | 0 | |
LN, lymph node; LNR, lymph node ratio.